SCHEMBL2474066

SCHEMBL2474066

COc1ccccc1NC(=O)NC(CCCN(C)C)c1ccc(C(=O)Nc2ccccc2N)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.62
UTS2R Q9UKP6 5/20 0.48
HDAC2 Q92769 4/20 0.47
HDAC6 Q9UBN7 3/20 0.47
HDAC3 O15379 3/20 0.47
HDAC10 Q969S8 3/20 0.47
HDAC4 P56524 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
CACNA1H O95180 2/20 0.46
CACNA1B Q00975 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
EPHA2 P29317 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3830929 0.87 UTS2R (0.51) HDAC1UTS2RHDAC6NPC1RAB9A
SCHEMBL2474421 0.86 HDAC1 (0.48) HDAC1UTS2RHDAC2HDAC6HDAC3
SCHEMBL3832758 0.84 UTS2R (0.49) HDAC1UTS2RHDAC2HDAC6HDAC3
SCHEMBL2478630 0.84 HDAC1 (0.56) HDAC1UTS2RHDAC2HDAC3NCOR2
SCHEMBL2473259 0.84 UTS2R (0.51) HDAC1UTS2RHDAC2HDAC3NCOR2
SCHEMBL3837712 0.83 UTS2R (0.48) HDAC1UTS2RHDAC2HDAC3NCOR2
SCHEMBL3831092 0.83 UTS2R (0.48) HDAC1UTS2RHDAC2HDAC3NCOR2
SCHEMBL2478995 0.82 HDAC1 (0.51) HDAC1UTS2RHDAC2HDAC3HDAC4
SCHEMBL2476829 0.82 UTS2R (0.49) HDAC1UTS2RHDAC2HDAC3NCOR2
SCHEMBL2474402 0.82 UTS2R (0.47) HDAC1UTS2RHDAC2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US claimed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP claimed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US claimed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP claimed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885UTS2R 11/4885HDAC2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.